Table 1. Patient demographics and baseline characteristics.
| Ciclesonide (N=75) | Budesonide (N=75) | P value | |
|---|---|---|---|
| Gender, F (%) | 38 (50.7) | 35(46.7) | 0.624 |
| Age, years | 51.2±18.3 | 55.5±15.4 | 0.125 |
| Body height, cm | 160.0±9.4 | 161.1±8.0 | 0.426 |
| Body weight, kg | 62.8±9.8 | 66.0±13.4 | 0.092 |
| BMI, kg/m2 | 24.5±3.3 | 25.4±3.3 | 0.195 |
| Smoking status | 1.000 | ||
| Nonsmoker, n (%) | 66 (88.0) | 65 (86.7) | |
| Ex-smokers, n (%)a | 9 (12.0) | 10 (813.3) | |
|
Pulmonary function | |||
| FVC, l | 2.9±1.1 | 2.9±0.9 | 0.942 |
| FVC, pred. % | 92.3±20.1 | 92.1±21.5 | 0.958 |
| FEV1, l | 2.2±0.9 | 2.1±0.7 | 0.424 |
| FEV1, pred. % | 82.6±19.8 | 81.6±19.0 | 0.744 |
| FEV1/FVC, % | 74.6±12.1 | 71.9±12.0 | 0.173 |
| MMEF, l/s | 1.9±1.2 | 1.7±0.9 | 0.075 |
|
Initial diagnosis of asthma | |||
| FVC, l | 2.4±0.8 | 2.4±0.7 | 0.929 |
| FVC, pred. % | 74.3±15.4 | 74.7±15.6 | 0.868 |
| FEV1, l | 1.6±0.6 | 1.6±0.5 | 0.776 |
| FEV1, pred. % | 59.5±13.0 | 59.9±16.8 | 0.885 |
| Change of FEV1, %b | 22.9±7.6 | 22.4±7.3 | 0.661 |
| FEV1/FVC, % | 67.6±11.3 | 59.9±16.8 | 0.399 |
| ACT score | 24.0±1.0 | 24.0±0.9 | 0.867 |
|
Previous medicine | |||
| Seretide, % | 66 (88.0) | 62 (82.7) | 0.356 |
| Symbicort, % | 9 (12.0) | 13 (17.3) | |
Abbreviations: ACT, asthma control test; F, female; FEV1, forced expiratory volume in 1 s; FVC, forced expiratory capacity; MMEF, maximum mid-expiratory flow; pred., predicted value.
a
Smoking history was less than 10 pack-years.
b
FEV1 was obtained 15 minutes after inhaled salbutamol (400 μg). Data are expressed as mean±s.d. or number (%).